EvodiaBio ApS

The company's activities comprise research, development, manufacture, and sale of sustainable aroma molecules and blends for the food and beverage industries as well as other relevant industries. During the year, the company initiated the commercial launch of its first product, Yops®. Activities included further investments in and commissioning of production equipment, development of production capabilities, and continued establishment of the commercial organisation and distribution setup to support market introduction across export markets.

The income statement for the financial year 1 January – 31 December 2025 shows a net loss of DKK 26,798,122, compared to a loss of DKK 21,106,598 in 2024. The loss reflects continued investments in scaling production capacity, the organisation, and commercial readiness.At 31 December 2025, the balance sheet shows equity of DKK 68,626,121, compared to DKK 52,423,684 at the end of 2024.During the financial year, the company completed a capital increase raising approximately DKK 44 million in new equity. The capital raise strengthens the company’s financial position and supports continued development, production scale-up, and commercialisation of the company’s products.In 2025, the company continued to invest significantly in property, plant and equipment to establish its production capabilities and support future growth.Management considers the financial result for the year to be in line with expectations given the company’s stage of development and ongoing investments in scaling the business.

No events materially affecting the assessment of the Annual Report have occurred after the balance sheet date.

Other contingent liabilities

Lease obligations under operating leases. Total future lease payments: DKK 1,310,381.

Charges and securityAs security for fulfillment of the leasing contract to the leasing company, the company has provided a deposit of DKK 1,853,400.